Prithvi Mruthyunjaya, MD,MHS’ Post

Veracyte, Inc. #Prostate #Decipher Prostate Genomic Classifier #NCCN Guidelines --Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines --The new NCCN Guidelines classify the Decipher Prostate test as Level 1B according to the “Simon Criteria,” which are published criteria for assigning a level of evidence for clinical biomarkers based on the quality and quantity of evidence available. NCCN summarizes the treatment implications for patients based on their Decipher score and the published evidence from analyses of multiple randomized, phase 3 clinical trials. https://lnkd.in/gV-BvR4P

The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer:-

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

Short interview from recent #ESMOTAT24 conference, where honorary awardee Prof. Funda Meric-Bernstam from MD Anderson Cancer Center, discusses progress made so far as well as remaining challenges related to ‘Implementing precision oncology: from genomics to ADCs’. Key takeaways: ·      Genomic testing has become more widely available, but oncologists face challenges in identifying actionable alterations and overcoming resistance to targeted treatments ·      Exciting to see whether the benefits of ADCs can be extended to patients with rare tumors ·      Community needs to address variability in patient access to molecular testing and approved treatments ·      Combining a variety of cancer research tools such as transcriptomics, proteomics, and immune profiling alongside genomics will enable more comprehensive characterization of the tumor, thereby enabling more effective therapeutic solutions #ESMOTAT24 #precisiononcology #ESMODailyReporter

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology

“For the longest time, people thought this is not something that can be commercialized.” Chantale Bernatchez, head of Process Development at CTMC / A joint venture between Resilience + MD Anderson Cancer Center The FDA has recently approved Iovance Biotherapeutics’ tumor infiltrating lymphocyte (TIL) therapy Amtagvi® for patients with unresectable or metastatic melanoma – marking the first cell therapy of its class to target a solid tumor. In an interview with Labiotech.eu, Chantale shared her insights into TIL therapy and what the first approval means for the cell and gene therapy sector. As Amtagvi® paves the way for many more TIL therapy approvals, it is imperative that logistical and reimbursement challenges are overcome, so that these therapies are not just approvable but accessible and affordable too. Read more ➡️ https://lnkd.in/dDBfZ5PU #CellTherapy #GeneTherapy #Biotechnology #ManufacturingBrighterFutures #AdvancedTherapies

I am glad to share with those of you interested in pharmacogenetics, lymphomas, and predictive biomarkers of tumor sensitivity/resistance to anticancer drugs our collaborative research article published today on Cancer Drug Resistance.

Tumor patients with mutant RAS possess a worse prognosis and shorter overall survival compared with those patients without RAS mutation. Emerging strategies have been recently developed for RAS-targeting therapy. This blog post explores the ‘undruggable’ oncology target RAS, inhibitory techniques used on downstream pathways, and the preclinical models available to test up-and-coming RAS targeted agents. #CancerResearch #Oncology